Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Israel Healthcare News.
Press releases published on June 3, 2025
New Collaboration Between Psifas and OpenDNA: Predicting Common Diseases Through AI and Genomic Data
EIN Presswire
·
June 3, 2025
HAIFA, ISRAEL, ISRAEL, June 3, 2025 /EINPresswire.com/ -- The Israeli National Initiative for Personalized Medicine, Psifas, and OpenDNA a Genomic AI biotech company have announced a strategic collaboration to develop artificial intelligence models that …
Teva Announces Pricing and Early Acceptance Results of its Debt Tender Offer
GlobeNewswire
·
June 3, 2025
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the pricing and early acceptance results of its previously announced tender offers (the “Offers”) to purchase for cash …
InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer
GlobeNewswire
·
June 3, 2025
MIAMI, June 03, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced the appointment of Michael Lawless, an …
Nanox to Participate in Sidoti Small Cap Conference
GlobeNewswire
·
June 3, 2025
PETACH TIKVA, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD (NASDAQ: NNOX) (“Nanox” or the “Company”), an innovative medical imaging technology company, today announced that it will participate in the Sidoti Small Cap Conference to be held …
Teva Announces Early Tender Results of its Debt Tender Offer, Increase to Tender Pool Caps and Total Maximum Amount and Election of Early Settlement
GlobeNewswire
·
June 3, 2025
TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“Teva”) announced today the early tender results in connection with its previously announced tender offers (the “Offers”) as specified below for …
Kamari Pharma Announces Closing of $23 Million Financing to Advance its First-In-Class Oral TRPV3 Inhibitor for Rare Genetic Skin Diseases
GlobeNewswire
·
June 3, 2025
Financing co-led by new investor BRM Group and existing investor Pontifax Lead program KM023 is a first-in-class oral TRPV3 inhibitor entering clinical development for the treatment of three rare genetic skin diseases; Olmsted syndrome, severe keratoderma …